Brain Cancer News and Research

RSS
There are two main types of brain cancer. Primary brain cancer starts in the brain. Metastatic brain cancer starts somewhere else in the body and moves to the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Also called glioma, meningioma.
Researchers identify potential therapeutic target for glioblastoma

Researchers identify potential therapeutic target for glioblastoma

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Researchers describe new progress in treatment of brain cancer, other neurological diseases

Researchers describe new progress in treatment of brain cancer, other neurological diseases

Scientists devise novel way to use stem cells in fight against brain cancer

Scientists devise novel way to use stem cells in fight against brain cancer

Viewpoints: Health law fails to control costs; GOP alternative 'worse than Obamacare'

Viewpoints: Health law fails to control costs; GOP alternative 'worse than Obamacare'

Discovery could prolong life of people living with glioblastoma

Discovery could prolong life of people living with glioblastoma

Research finding offers new insights into the cause of glioblastoma

Research finding offers new insights into the cause of glioblastoma

Viewpoints: Ebola myths; Sen. McCain's 'opportunistic alarmism'; Gov. Jindal on CDC's misspent resources

Viewpoints: Ebola myths; Sen. McCain's 'opportunistic alarmism'; Gov. Jindal on CDC's misspent resources

Viewpoints: Walmart and Obamacare; negative views continue of health law; Ebola preparedness

Viewpoints: Walmart and Obamacare; negative views continue of health law; Ebola preparedness

CUMC researchers use innovative algorithm to find driving force behind aggressive form of glioblastoma

CUMC researchers use innovative algorithm to find driving force behind aggressive form of glioblastoma

VAL-083 drug compound shows promise against non-small cell lung cancer

VAL-083 drug compound shows promise against non-small cell lung cancer

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

Viewpoints: Relatively few face insurance cancellations; new doctor payment site is 'impenetrable'

Viewpoints: Relatively few face insurance cancellations; new doctor payment site is 'impenetrable'

Brain cancer patients can benefit from Rapamycin drug

Brain cancer patients can benefit from Rapamycin drug

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

CytRx begins aldoxorubicin Phase 2b clinical trial in patients with extensive-stage SCLC

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

FDA grants multiple Orphan Drug Designations for CytRx's aldoxorubicin

Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Using handheld Raman scanner researchers completely removed brain tumors

Using handheld Raman scanner researchers completely removed brain tumors

One-two punch designed to knock out most dangerous brain cancer

One-two punch designed to knock out most dangerous brain cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.